Anzeige
Meldung des Tages: 15 % Kupfer-Äquivalent: Steckt hier der nächste Rohstoff-Gigant für KI & Energiewende?

AbbVie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
179,20 €
+1,00 €
+0,56%
09:52:49 Uhr
Depot/Watchlist
Marktkapitalisierung *
345,80 Mrd. €
Streubesitz
24,69%
KGV
21,69
Dividende
5,85 EUR
Dividendenrendite
3,02%
Nachhaltigkeits-Score
46 %
Index-Zuordnung
S&P 500
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,36: MK4Z0E
Werbung

AbbVie News

30.07.25 - PR Newswire
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata PR Newswire
29.07.25 - PR Newswire
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic ...
22.07.25 - PR Newswire
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project PR Newswire
10.07.25 - PR Newswire
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-​in-Class CD38×BCMA×CD3 Trispecific Antibody PR Newswire
10.07.25 - PR Newswire
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-​in-Class CD38×BCMA×CD3 Trispecific Antibody PR Newswire
30.06.25 - PR Newswire
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology PR Newswire
30.06.25 - PR Newswire
U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance ...
30.06.25 - PR Newswire
AbbVie to Host Second-Quarter 2025 Earnings Conference Call
AbbVie to Host Second-​Quarter 2025 Earnings Conference Call PR Newswire
29.06.25 wallstreetONLINE Redaktion
Dividenden im Fokus: Fünf Dividenden-Favoriten für das zweite Halbjahr
Wegen geopolitischer Risiken bleiben solide Dividendenaktien weiter gefragt. Laut CNBC Pro bieten diese fünf Favoriten stabile Erträge, Analystenvertrauen und teils ein ...
22.06.25 wallstreetONLINE Redaktion
Blockbuster-Kandidaten: 14 Aktien & 2 ETFs mit Milliardenpotenzial, die wie Bill Gates Alzheimer angehen
Viele forschende Pharmaunternehmen arbeiten intensiv an neuen Alzheimer-​Mitteln, die in den kommenden Jahren auf den Markt kommen könnten. Dies sind die ...
20.06.25 - PR Newswire
AbbVie Declares Quarterly Dividend
AbbVie Declares Quarterly Dividend PR Newswire
18.06.25 - PR Newswire
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-​to-Head Study Compared to ...
16.06.25 - PR Newswire
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-​Risk Myelodysplastic Syndromes PR Newswire
11.06.25 - PR Newswire
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus PR Newswire
03.06.25 - PR Newswire
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals PR Newswire
03.06.25 - PR Newswire
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference PR Newswire
30.05.25 - PR Newswire
AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
AbbVie Partners with Chicago Cubs on "Striking Out Cancer" PR Newswire
30.05.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV PR Newswire
29.05.25 - PR Newswire
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire
27.05.25 - PR Newswire
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio
AbbVie Features New Data Across Difficult-​to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio PR Newswire

Newssuche

Videos

newspaper
19.03.26
COUNTER HUNTER Strategie Einführung
Live-​Seminar am 29.3. ab 14 Uhr! Wie immer wird die Schulung auch aufgezeichnet und allen ... Mehr »